FOR US HEALTH CARE PROFESSIONALS ONLY
Select a section to view materials
APOKYN is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) associated with advanced PD.1
GOCOVRI is an NMDA receptor antagonist indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing “off” episodes.2
ONAPGOTM is a dopaminergic agonist indicated for the continuous treatment of motor fluctuations (“off” episodes) in patients with PD that are not adequately controlled with oral levodopa and one or more adjunct PD medications.
References: 1. APOKYN® (apomorphine hydrochloride injection). Package insert. Supernus Pharmaceuticals, Inc. 2. GOCOVRI® (amantadine). Package insert. Supernus Pharmaceuticals, Inc. 3. ONAPGOTM (apomorphine hydrochloride), for subcutaneous infusion. Package Insert. Supernus Pharmaceuticals, Inc.
